Advertisement

ESMO

ESMO

ESMO: Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

Sep 24, 2020

Lorlatinib is a third generation ALK tyrosine kinase inhibitor. The phase 3 CROWN study shows...

ESMO: Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

Sep 24, 2020
ESMO: PD-L1 density, a new predictive biomarker in NSCLC

Sep 24, 2020
ESMO: Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence

Sep 24, 2020

ESMO: No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC

Sep 24, 2020

The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer...

ESMO: Is adding an immune checkpoint inhibitor to targeted therapy the right approach?

Sep 24, 2020
ESMO: Is KRAS Finally ’Druggable’?

Sep 23, 2020
ESMO: Adjuvant Osimertinib Achieves Significant Benefit in EGFR Positive NSCLC

Sep 22, 2020
ESMO: Radiation Fails to Improve Lung Cancer Outcomes

Sep 22, 2020

Advertisement